Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector

J.A. Kortekaas, S.M. de Boer, J. Kant, R.P.M. Vloet, A.F.G. Antonis, R.J.M. Moormann

Research output: Contribution to journalArticleAcademicpeer-review

65 Citations (Scopus)


Rift Valley fever virus (RVFV) causes recurrent large outbreaks among humans and livestock. Although the virus is currently confined to the African continent and the Arabian Peninsula, there is a growing concern for RVFV incursions into countries with immunologically naive populations. The RVFV structural glycoproteins Gn and Cc are preferred targets in the development of subunit vaccines that can be used to control future outbreaks. We here report the production of Gn and Cc by a recombinant vaccine strain of the avian paramyxovirus Newcastle disease virus (NDV) and demonstrate that intramuscular vaccination with this experimental NDV-based vector vaccine provides complete protection in mice. We also demonstrate that a single intramuscular vaccination of lambs, the main target species of RVFV, is sufficient to elicit a neutralizing antibody response. (C) 2010 Elsevier Ltd. All rights reserved.
Original languageEnglish
Pages (from-to)4394-4401
Issue number27
Publication statusPublished - 2010


  • newcastle-disease-virus
  • neutralizing antibodies
  • envelope glycoproteins
  • monoclonal-antibodies
  • respiratory-tract
  • lethal infection
  • avian influenza
  • protects mice
  • saudi-arabia
  • i interferon


Dive into the research topics of 'Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector'. Together they form a unique fingerprint.

Cite this